COVID–19 in teriflunomide-treated patients with multiple sclerosis.Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R.J Neurol. 2020 Jun 3. doi: 10.1007/s00415-020-09944-8.
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
Here’s another one
Mild COVID–19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.Möhn N, Saker F, Bonda V, Respondek G, Bachmann M, Stoll M, Wattjes MP, Stangel M, Skripuletz T.